Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer.

Authors:
Wang Y; Min J; Deng X; Feng T; Hu H and 8 more

Journal:
Acta Pharm Sin B

Publication Year: 2023

DOI:
10.1016/j.apsb.2023.05.005

PMCID:
PMC10692362

PMID:
38045063

Journal Information

Full Title: Acta Pharm Sin B

Abbreviation: Acta Pharm Sin B

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"with compounds29c (7ymk) can be accessed from the rcsb protein data bank ( www rcsb org ) 4 9 pk studies were conducted in balb/c female mice ( n = 3 mice/group)."

Code Sharing
Evidence found in paper:

"Conflicts of interest The authors declare no conflicts of interest."

Evidence found in paper:

"The work was supported by National Key R&D Program of China (2020YFA0908800, 2021YFC2100300), 10.13039/100014717National Natural Science Foundation of China (82273774, 82073690, 81773557, 82173676, 82103994), the Fundamental Research Funds for the Central Universities of China (2042022kf0056), and the China Postdoctoral Science Foundation (2020M672435)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025